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The p38 mitogen-activated protein kinase regulates the
synthesis of pro-inflammatory cytokines in response to
stimulation by a diverse set of stress signals. Various different
chemotypes and clinical candidates that inhibit p38 function
have been reported over the years. In this publication, the
novel structure of p38 cocrystallized with the clinical
candidate TAK-715 is reported. Owing to the impact of
crystallization conditions on the conformation of protein
kinases (and in particular p38), the structures of complexes
of p38 with SB-203580, SCIO-469 and VX-745 have also
been determined to enable in-depth comparison of ligand-
induced protein conformations. The impact of experimental
conditions on p38–inhibitor complex structures, most
importantly soaking versus cocrystallization, is discussed.
Analysis of the structures and quantification of the protein–
ligand interactions couples ligand-induced protein conforma-
tions to the number of interactions and to inhibitor selectivity
against the human kinome. This shows that for the design of
novel kinase inhibitors, selectivity is best obtained through
maximization of the number of interactions throughout the
ATP pocket and the exploitation of specific features in the
active site.
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PDB References:
p38–SB-203580, 3zs5;
p38–TAK-715, 3zsg;
p38–SCIO-469, 3zsh;
p38–VX-745, 3zsi.
1. Introduction
The p38 mitogen-activated protein kinase (MAPK) pathway
regulates various cellular processes, including inflammation,
immune response, cell survival and differentiation (Han et al.,
1994; Lee et al., 1994). The pathway is activated upon stimu-
lation by a diverse set of extracellular stress signals including
bacterial endotoxic lipopolysaccharide (LPS), heat shock,
osmotic stress, arsenite and cytokines (Han et al., 1994, 1997;
Rouse et al., 1994; Freshney et al., 1994). The pathway controls
the production and secretion of pro-inflammatory cytokines
such as tumour necrosis factor- (TNF), interleukin-6 (IL-6)
and interleukin-1 (IL-1), amongst others (Lee et al., 1994).
Selective inhibition of any of these three cytokines using
antibody therapies has shown efficacy both in animal models
and in the clinical setting for the treatment of autoimmune
diseases such as rheumatoid arthritis (RA) and psoriasis
(Maini et al., 1999; Nishimoto et al., 2009).
Owing to its central role in the regulation of cytokine
production and inflammatory disease, many pharmaceutical
companies have actively pursued p38 as a drug target. Some
disappointing clinical data have led many to conclude that
p38 inhibitors are not suitable for the treatment of RA
(Genovese, 2009; Hammaker & Firestein, 2010). However,
one highly selective p38 inhibitor, PH-797804, was recently
reported to have demonstrated efficacy over the entire six-
week time course of a Phase II clinical trial for the treatment
of chronic obstructive pulmonary disease (COPD; MacNee et
al., 2010). The discovery that inhibition of p38 activity has
potential for the anti-inflammatory treatment of COPD is
likely to trigger renewed interest in modulating the activity of
the p38 signalling pathway using small-molecule inhibitors.
In order to contribute to the development of novel leads and
candidates, we sought to compare the binding characteristics
of various p38 clinical candidates and other classical inhibi-
tors, including TAK-715.
TAK-715 has been reported to demonstrate strong inhibi-
tory activity in cell-based assays, good bioavailability in mice
and rats, and significant efficacy in a long-term disease model,
i.e. rat adjuvant-induced arthritis. A specific feature of this
compound is its lack of inhibition of cytochrome P450s, with
the potential to lower the risk of drug–drug interactions and
hepatotoxicity (Miwatashi et al., 2005). The compound has
been tested in a Phase II clinical trial for the treatment of RA
(http://clinicaltrials.gov/ct2/show/NCT00760864). The study
has been completed, but the results have not yet been
communicated.
Various X-ray structures have been published of p38 in
different functional and pharmacologically relevant states, i.e.
from nonphosphorylated ligand-free forms via (phosphory-
lated) substrate peptide-bound states to nonphosphorylated
conformations bound to many different small-molecule inhi-
bitors (Wilson et al., 1996; Wang et al., 1997; Chang et al., 2002;
Akella et al., 2010). NMR structural data have also been
obtained, but only 64% of the backbone could be assigned,
which was attributed to flexibility of the catalytic C-helix,
activation loop and C-terminal subdomains (Vogtherr et al.,
2005, 2006). The combined structural data illustrate that p38
exhibits considerable protein flexibility, even for a protein
kinase, as the hinge, Gly-rich loop, activation loop, catalytic
helix, peptide-docking groove and p38-specific insert can all
adopt several different conformational states.
Previous structures of p38 bound to SB-203580 (Tong et
al., 1997; Wang et al., 1998; Vogtherr et al., 2006; Simard et al.,
2009) show that the binding conformation (Fig. 1) can differ
substantially depending on the experimental conditions. For
example, PDB entry 1a9u (Wang et al., 1997) shows the DFG
segment in its active DFG-in conformation and PDB entry
3gcp (Simard et al., 2009) shows the inactive DFG-out fold,
whilst PDB entry 2ewa (Vogtherr et al., 2006) presents both
conformations. PDB entries 1a9u and 2ewa result from
soaking experiments with relatively different conditions,
whilst PDB entry 3gcp was produced by cocrystallization of
the protein with the ligand. It is clear that for a fair compar-
ison of different p38–inhibitor complexes similar conditions
should be used to produce the various structures. We therefore
report the novel structure of p38 cocrystallized with TAK-
715, as well as new high-resolution structures of p38 bound
to SB-203580, SCIO-469 and VX-745. As the experimental
conditions are similar for all cocrystals, an unbiased compar-
ison of the binding features of each of the ligands is possible.
The impact of these conditions is evaluated.
The X-ray structures point to marked conformational flex-
ibility of the p38 protein. This structural information was
combined with publicly available protein kinase selectivity
profiles and contact-residue information to generate an in-
depth understanding of the relationships between compound
chemical structure, compound-induced protein conformation
and selectivity.
2. Experimental procedures
2.1. Cloning, expression and purification
The crystallization construct was amplified from human
p38 cDNA with N- and C-termini as described previously
(Wang et al., 1997). p38 was cloned in a Gateway-adapted
expression vector (derived from pMal-c2x, NEB) with an
N-terminal His tag followed by a thrombin protease cleavage
site. The purified protein sequence starts with a Gly-Ser-His
thrombin cleavage-tag remnant followed by the p38 sequence
(UniProt Q16539, MK14_HUMAN) starting at Ser2 and
containing all residues up to the natural C-terminus. After
thrombin cleavage, the N-terminal sequence starts with
GSHSQERPT. The expression vector was transformed into
Escherichia coli BL21 (DE3) cells to express the recombinant
fusion protein. During subsequent optimization tests, the
construct was transformed into the E. coli Rosetta (DE3)
strain, which gave improved protein yields. To express the
recombinant protein, a starter culture was grown overnight
in 50 ml minimal medium containing 20 mg ml1 chloram-
phenicol and 100 mg ml1 ampicillin. The next day, this
preculture was used to inoculate a 4 l fermentor filled with
standard medium and 100 mg l1 ampicillin. The culture was
grown at 303 K to an OD640 of 24, after which the temperature
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Figure 1
Comparison of the binding conformation of SB-203580 in previously
published structures: PDB entry 1a9u, red; PDB entry 2ewa, green; PDB
entry 3gcp, blue; PDB entry 3mpa, yellow; PDB entry 3obg, magenta.
was lowered to 293 K and additional sorbitol and 0.3 mM
IPTG were added. After 4 h, at an OD640 of 33, the cells were
harvested by centrifugation at 6000 rev min1 for 30 min in a
Sorvall GS3 rotor and the cell pellets were stored at 253 K.
The bacterial pellet was suspended in lysis buffer and
disrupted in a high-pressure liquid homogenizer (Avestin; two
runs at 120 kPa). The lysate was cleared by a 40 min spin at
20 000 rev min1 in a Sorvall centrifuge with an SS34 rotor.
The supernatant was applied onto Ni–NTA agarose beads
(Qiagen) and His-p38 was eluted with 250 mM imidazole in
lysis buffer. The His tag was removed by thrombin cleavage
and the protein was further purified
by anion-exchange chromatography
(Mono Q HR 10/100 GL, GE Health-
care). The final polishing step was
performed by size-exclusion chromato-
graphy on a Superdex 75 column (XK
16/60, GE Healthcare). High-purity
peak fractions were pooled and
concentrated to 18 mg ml1 (as deter-
mined from the A280). Protein in 20 mM
HEPES pH 7.1, 50 mM NaCl, 10 mM
DTT, 5% glycerol, 0.1 g l1 methionine
was flash-cooled in dry ice/ethanol and
stored at 203 K.
2.2. Crystallization and data collection
The previously described crystal-
lization conditions (Bukhtiyarova et al.,
2004) were optimized for cocrystalliza-
tion with inhibitors using our batch of
protein. Inhibitor stocks were freshly
made by dissolving dry powder in 100%
DMSO to 100 mM final concentration.
The inhibitor stock was added to the
protein in a threefold molar excess and
incubated on ice for at least 10 min.
p38 was cocrystallized using the
hanging-drop vapour-diffusion method
in pre-greased VDX plates (Hampton Research) on silico-
nized cover slides at room temperature. The crystals grew in
0.1MMES pH 6.5, 19–28% PEG 4000, 50–100 mMN-octyl--
d-glucoside, 0–5 mMDTT to typical dimensions of 300 70
60 mm. The crystals were cryoprotected using 20–25% ethy-
lene glycol in the crystallization condition. Crystals cocrys-
tallized with SB-203580 were flash-cooled in liquid nitrogen
and a high-resolution data set was collected at the ESRF on a
fixed-wavelength beamline (0.933 A˚) using an ADSCQ4 CCD
detector. Crystals cocrystallized with TAK-715, SCIO-469 and
VX-745 were cooled in the cryostream of an in-house X-ray
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Table 1
Data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Data set SB-203580 TAK-715 SCIO-469 VX-745
Data collection
Space group P212121 P212121 P212121 P212121
Unit-cell parameters
(A˚)
a = 67.49,
b = 70.04,
c = 75.01
a = 68.54,
b = 70.17,
c = 74.76
a = 68.72,
b = 70.08,
c = 74.29
a = 65.55,
b = 73.65,
c = 76.57
Resolution (A˚) 1.60 (1.69–1.60) 1.89 (2.00–1.89) 1.93 (2.04–1.93) 2.01 (2.12–2.01)
Rmerge† 0.082 (0.88) 0.065 (0.45) 0.096 (0.94) 0.105 (1.561)
Mean I/(I) 8.0 (0.8) 9.6 (1.6) 7.1 (0.8) 6.6 (0.5)
Completeness (%) 93.8 (75.3) 100.0 (100.0) 99.2 (96.6) 96.8 (89.9)
Multiplicity 6.9 (5.9) 6.2 (6.1) 4.6 (4.5) 4.4 (4.2)
Refinement
Resolution (A˚) 51–1.60 35–1.89 37–2.05 38–2.40
No. of reflections 42175 27922 21887 14272
Rwork/Rfree (%) 18.34/21.58 18.93/23.30 20.54/25.51 23.06/27.07
No. of non-H atoms
Total 3191 3138 2973 2882
Protein 2825 2772 2711 2704
Inhibitor 27 29 36 28
Octyl glucoside 36 20 20 20
Solvent 303 317 206 130
Average B factor (A˚2)
Overall 22.5 23.8 31.7 16.5
Protein 21.8 22.7 31.0 16.0
Inhibitor 22.9 27.3 42.8 41.1
Octyl glucoside 31.2 30.5 41.5 44.0
Solvent 28.0 32.4 36.7 18.2
R.m.s.d.
Bond lengths (A˚) 0.011 0.009 0.012 0.005
Bond angles () 1.4 1.2 1.3 0.88
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ (Evans, 2006).
Figure 2
Chemical structures of the four cocrystallized p38 inhibitors.
generator (Rigaku MicroMax-007 HF) and the data were
collected using an R-AXIS IV++ image-plate detector. Data-
collection statistics are given in Table 1.
2.3. Structure determination
X-ray diffraction data were processed with MOSFLM and
SCALA from the CCP4 package (Winn et al., 2011). All four
structures were determined by rigid-body refinement, using a
structure of p38 from an undisclosed but well refined 1.5 A˚
resolution p38 structure stripped of solvent and inhibitor as
a starting model. No further repositioning with molecular-
replacement programs was needed. The structural models
were adjusted by several rounds of manual model building
using Coot (Emsley & Cowtan, 2004) and positional refine-
ment using REFMAC (Murshudov et al., 2011). Water mole-
cules were added using the Coot Find Waters routine within
CCP4 and were inspected manually using Coot. A total of 5%
of the observations were excluded from refinement and used
for calculation of the Rfree factor (Bru¨nger, 1992). Refinement
statistics and the quality of the structures are summarized in
Table 1.
2.4. Structure comparisons, contact-residue identification
and frequency determination
Structure comparisons were made using Merck’s in-house
Protein Kinase Structure Database (publication in prepara-
tion) containing all public domain protein kinase structures.
Analyses of structures in this database was used to perform
comparisons between features seen in the structures presented
here and those in other public domain structures.
All structures were imported into YASARA (Krieger et al.,
2002), where any heteroatoms other than the four inhibitors
were deleted. For each of the complexes, a radius of 4 A˚ was
used to identify any residue in possible contact with the ligand.
The position of each of these residues was mapped onto the
human eukaryotic protein kinase (ePK) multiple sequence
alignment (MSA; Manning et al., 2002), which was obtained
via http://kinase.com. The relative frequency of the p38
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Figure 3
Structures of p38 bound to SB-203580 and TAK-715. Inhibitors and specific amino acids are shown in stick representation and labelled throughout the
figure. Hydrogen-bonding interactions are indicated by dotted lines. (a) ATP pocket of p38 with bound TAK-715. (b) ATP pocket of p38 with bound
SB-203580. (c) Superposition of structures with SB-203580 and TAK-715. The adenine and phosphate-binding regions (AR and PR) and the front and
back pockets (FP and BP) are labelled. (d) Superposition of structures with SB-2032580 presented here and from the public domain (PDB entry 1a9u;
green). Specific residues are labelled to indicate conformational differences. The activation loops in both structures are labelled.
amino acids at each specific position in the ePK MSA was
calculated. All selected residues and their corresponding
frequencies of occurrence in the kinome are summarized in
Fig. 6.
3. Results and discussion
3.1. Overall structures of p38a–inhibitor complexes
Structures have been determined of p38 bound to TAK-
715 and the three classic inhibitors SB-203580, VX-745 and
SCIO-469. The chemical structures of these compounds are
shown in Fig. 2. Overall, the four protein structures are similar.
The SCIO-469 and TAK-715 complexes have r.m.s.d.s from
the p38–SB-203580 complex of 0.369 and 0.138 A˚, respec-
tively. The p38–VX-745 complex shows larger changes in
orientation between lobes compared with the SB-203580-
bound structure, with overall, N-terminal lobe and C-terminal
lobe r.m.s.d. values of 1.227, 0.338 and 0.470 A˚, respectively.
All four inhibitors were cocrystallized with human p38
in the presence of octyl glucoside, and one molecule of the
detergent is bound in the lipid-binding pocket in each struc-
ture. Significant differences between the four structures are
restricted to the ATP-binding pocket, where ligand-induced
conformational differences were observed in the hinge region,
the Gly-rich loop and the DFG motif.
3.2. Novel X-ray structure of p38a–TAK-715
The structure of p38–TAK-715 was determined at 1.89 A˚
resolution (R factor = 17.6%, Rfree = 23.1%). The binding of
TAK-715 to p38 is shown in Fig. 3(a). Several interactions are
formed to stabilize this complex. The pyridine N atom of the
inhibitor makes a hydrogen bond to the main-chain NH of
Met109. The amide NH of TAK-715 is hydrogen bonded to
the main-chain carbonyl of Met109. The N atom of the thia-
zole core forms a direct hydrogen bond to the active-site
Lys53, which also interacts with Glu71. Lys53 and Asp168 are
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Figure 4
Structures of p38 bound to SCIO-469 and VX-745. Inhibitors and specific amino acids are shown in stick representation and labelled throughout the
figure. Hydrogen-bonding interactions are indicated by dotted lines. (a) ATP pocket of p38 with bound SCIO-469. (b) ATP pocket of p38 with bound
VX-745. (c) Superposition of structures with SCIO-469 and VX-745. (d) Overlay of previously published p38–VX-745 structures (PDB entry 3fc1, red;
PDB entry 3hp5, magenta) and the complex presented here (cyan). Specific residues are labelled to indicate conformational differences (our structure,
black; PDB entry 3fc1, magenta)
connected through water-mediated hydrogen bonds. Further-
more, the thiazole core is stacked upon the phenyl side chain
of Phe169 and the ethyl group of the thiazole is within van der
Waals distance of Tyr35. The 3-methylphenyl moiety binds in
the hydrophobic back pocket and the phenyl moiety of the
amide is located in the front pocket of p38, which is planar
and hydrophobic in this conformation of the protein.
Surprisingly, the DFG group is in a DFG-out conformation
even though no detergent molecule is present in the DFG
pocket.
3.3. X-ray structure of p38a–SB-203580
The structure of p38–SB-203580 was determined at 1.7 A˚
resolution (R factor = 18.3%, Rfree = 21.6%), the highest
resolution published to date. Five structures of p38 bound to
this inhibitor are available in the public domain (PDB entries
1a9u, 2ewa, 3gcp, 3obg and 3mpa; Wang et al., 1998; Vogtherr
et al., 2006; Simard et al., 2009). Of these, PDB entry 3gcp is
the most similar to our structure, with an overall r.m.s.d.
between the two structures of 0.261 A˚, owing to it being
cocrystallized under similar conditions. Nevertheless, and
owing to the high resolution, the structure presented here
contains more information, including the detailed water-
mediated hydrogen-bonding network. The binding of SB-
203580 to the active site of p38 is shown in Fig. 3(b). In the
structure presented here the DFG-motif has a ‘DFG-out’
conformation facilitating aromatic stacking interactions
between the imidazole core of the inhibitor and the phenyl
side chain of Phe169 of the DFG sequence. The DFG-out
conformation appears to be stabilized by the presence in the
DFG pocket of one molecule of the detergent octyl glucoside,
which was used as an additive during crystallization. As
mentioned previously, the DFG-in conformation observed in
PDB entry 1a9u (see comparison in Fig. 3d) was obtained via
a soaking methodology. PDB entry 2ewa is also a soaked
complex, but shows a double DFG-in and DFG-out confor-
mation. It appears that soaking prohibits the more stable
DFG-out conformation being achieved or stabilized.
3.4. X-ray structure of p38a–SCIO-469
The structure of p38–SCIO-469 was determined at 2.05 A˚
resolution (R factor = 20.0%, Rfree = 25.7%) and is similar to
the 2.25 A˚ resolution structure with PDB code 3hub (Simard
et al., 2010), with an overall r.m.s.d. between the complexes
of 0.303 A˚. Two distinguishing features are displayed in this
complex, namely the hinge flip and the curling of the Gly-rich
loop over the inhibitor.
The central carbonyl O atom of SCIO-469 forms bidentate
hydrogen bonds to the main-chain amides of Met109 and
Gly110 in the hinge region (Fig. 4a). This interaction is
facilitated by a peptide flip between these two residues. The
dimethylpiperazine does not make any polar interactions with
the protein, but makes extensive van der Waals interactions
with the side chain of Tyr35; short contacts (2.4 and 2.8 A˚)
appear to exist between one of the methyl groups of the
piperazine and the CB and CG atoms of Tyr35. Density for
this methyl is lacking, but neither SCIO-469 nor Tyr35 can be
built in alternative conformations. The position of Tyr35 is
stabilized by a polar interaction between this residue and the
lone pair of the indole N atom of SCIO-469. This conforma-
tion of the Gly-rich loop has only previously been observed in
a relatively small number of protein kinases, namely Abl
(Cowan-Jacob et al., 2007), FGFR1 (Tsai et al., 2008), Met
(D’Angelo et al., 2008), EphA3 (PDB entry 3dzq; Structural
Genomics Consortium, unpublished work), AurA (PDB entry
3dj5; R. A. Elling, D. Erlanson, W. Yang, B. T. Tangonan, S. K.
Hansen & M. J. Romanowski, unpublished work) and p38
(Patel et al., 2009).
3.5. X-ray structure of p38a–VX-745
The structure of p38–VX-745 (Fig. 4b) was determined at
2.4 A˚ resolution (R factor = 23.06%, Rfree = 27.07%). This
structure is similar to PDB entries 3fc1 (r.m.s.d. of 0.452 A˚)
and 3hp5 (r.m.s.d. of 0.316 A˚) (Pearlman, 2005; Selness et al.,
2009) in the way that VX-745 binds to the hinge, back and
front pockets (Fig. 4d). Even though the resolution is slightly
lower than that of 3hp5, some of the features of the protein
that were not well defined in the previously published struc-
tures are clearly visible in ours, in particular the Gly-rich loop
and parts of the activation loop. This might arise from the
cocrystallization approach adopted, whereas PDB entry 3hp5
was obtained by soaking experiments. The Gly-rich loop
shows an extended conformation, with its edge residue, Tyr35,
pointing away from the ATP pocket and occupying the posi-
tion that Arg67 occupies in PDB entry 3fc1. The conformation
of the beginning of the activation loop is markedly different
compared with previous structures (in a DFG-in conforma-
tion), with the complex presented here showing an uncommon
DFG-out conformation. Phe169 is positioned outside the
DFG pocket, but points away from the hinge. This confor-
mation is quite rare; it has been observed twice before and
only in p38 (Wrobleski et al., 2008). Leu171 points into the
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Figure 5
Comparison of the ATP pockets of human p38 bound to SB-203580
(magenta), TAK-715 (blue), SCIO-469 (grey) and VX-745 (cyan).
ATP pocket and interacts with the dichlorophenyl group of
VX-745 that binds in the front pocket. This means that the
ATP pocket is partially closed and that the G-loop and the
activation loop are in contact via face-to-edge interactions of
the side chains of Tyr35 and Phe169.
3.6. Structure comparisons
On the basis of the determination of the four structures
presented here, as well as a large number of proprietary p38–
inhibitor structures (data not shown), it has become clear that
ligand-induced p38 conformations with a DFG-out state as in
Fig. 3 are likely to cocrystallize relatively quickly (1–3 d) and
often result in high-resolution structures (1.5–2.5 A˚) even
using an in-house X-ray radiation source. Conversely, p38–
ligand complexes with a DFG-in conformation often only
crystallize after a few weeks and diffract relatively weakly, i.e.
to about 2.5–3.0 A˚. Consistent with these observations, the
structures presented here show that the DFG-out conforma-
tions (Fig. 3) have a relatively compact structure with a ‘low’
Gly-rich loop and aromatic stacking interactions between
inhibitor, Tyr35 and Phe169, whereas the DFG-in conforma-
tions contain a ‘high’ Gly-rich loop that exhibits far fewer
interactions with the relevant inhibitors (Fig. 4). As cocrys-
tallization was conducted under identical conditions, these and
other structural differences between the four protein–ligand
structures can be attributed to ligand induction, enabling a
thorough comparison of the structural details and coupling to
kinase selectivity profiles.
Comparison of the four ATP regions shows that the protein
conformations cluster into two groups: one group comprises
TAK-715 and SB-203580, while the other contains SCIO-469
and VX-745 (Fig. 5). SB-203580 and TAK-715 bind relatively
‘high’ in the ATP pocket, occupying the hydrophobic back
pocket, the adenine region and the front pocket of p38 as
well as extending to most of the length of the Gly-rich loop,
compared with the other two compounds, which mostly bind in
the back, adenine and front pockets. Consequently, the Gly-
rich loop in the former two structures is pushed upward in
an open conformation, whereas this loop adopts a ‘closed’
conformation upon binding SCIO-469 and VX-745. The only
interaction conserved in all four structures is that between a
substituted phenyl in each compound and the hydrophobic
back pocket of p38.
The binding modes of SB-203580 and TAK-715 to p38 are
shown in Fig. 3(d). Both molecules bind to similar areas of the
ATP pocket such as the adenine, sugar and back-pocket
regions and both compounds induce DFG-out and Tyr35-in
conformations, resulting in a relatively flat ATP pocket. The
only significant difference is the fact that TAK-715 reaches
further into the front pocket through its benzamide group,
whereas SB-203580 does not.
The compounds in the other cluster, SCIO-469 and VX-745,
bind similarly and induce similar protein conformations
(Fig. 4c). Both compounds interact with the hinge, front and
back pockets but do not contact the sugar- and phosphate-
binding regions. A peptide flip is induced in the hinge, which
results in the presentation of two hydrogen-bond donors in
the ATP pocket, a clear difference from the acceptor–donor–
acceptor pattern normally present in the ATP pocket of
protein kinases. It has been noted previously that the peptide
flip is energetically accessible by the presence of a glycine
residue (Gly110) at the appropriate position in the hinge
(Xing et al., 2009), that this residue is specific to the -, - and
-isoforms of p38 and that this feature could be exploited in
future p38-inhibitor design (Fitzgerald et al., 2003). Analysis
of the PDB shows that this peptide flip has been observed
previously in p38 (Xing et al., 2009) and in the protein
kinases haspin (Eswaran et al., 2009) and ERK2 (Kinoshita et
al., 2006). Haspin is indeed one of 42 kinases that exhibit a
glycine residue at the relevant position (Manning et al., 2002).
In ERK2, the peptide flip of Glu109 in the position equivalent
to Gly110 is tolerated because two disadvantageous factors
in the binding of the compound are settled by this motion
(Kinoshita et al., 2006). The recently reported p38 inhibitor
PH-797804 induces a peptide flip similar to that observed in
the VX-745 and SCIO-469 complexes (Xing et al., 2009).
The most significant differences between the two structures
are the conformations of the Gly-rich loop and the DFG
segment. The Gly-rich loop is completely curled up in the
SCIO-469 structure but adopts a strand–turn–strand structure
upon binding VX-745. The DFG motif is in an unusual DFG-
out conformation in the p38–VX-745 complex, with the
Phe169 side chain pointing towards the C helix.
3.7. Structure–selectivity relationships
The four inhibitors discussed in this paper induce different
protein conformations and make contacts with different resi-
dues. In addition, the inhibitors exhibit different kinase
selectivity profiles.
SB-203580 shows limited selectivity, as determined by
profiling 38 protein kinase inhibitors in an assay panel
comprising 317 human protein kinases (Karaman et al., 2008).
SB-203580 was found to inhibit kinase activity with values
below 1 mM in 18 assays and below 10 mM in 43 assays. The
targets inhibited were distributed across all subfamilies in
the kinome. This relative lack of selectivity may be explained
using the X-ray structure described here. The compound is
bound mostly in regions that are conserved in protein kinases
for the binding of ATP. The only group that extends into
regions unrelated to function and thus divergent in kinase
structures is the fluorophenyl group, which binds into the back
pocket via the gatekeeper residues Thr106 and Lys53. This will
generate selectivity against kinases that contain large gate-
keeper residues. In the kinome, the majority of enzymes
(72%) have medium large to large gatekeepers. These kinases
(with, for example, Phe, Trp or Tyr gatekeepers) are indeed
unable to bind SB-203580 with high affinity. Of the 19 kinases
strongly inhibited by SB-203580, 12 contain a small Thr and
seven a medium-sized (but flexible) Met gatekeeper, both of
which allow access to the back pocket. Another interaction
between p38 and SB-203580 is the aromatic stacking inter-
action between the phenyl group of the inhibitor and Tyr35,
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which points into the ATP pocket. Some 84% of the kinome
contains a Tyr (21%) or Phe (63%) that would facilitate a
similar interaction. Clearly, the interaction with Tyr35 does not
contribute greatly to kinase selectivity.
Based on the structure comparison between SB-203580 and
TAK-715, TAK-715 may be expected to be more selective
than SB-203580 as it extends further into the front pocket
(Fig. 3c). TAK-715 has been reported to be selective over
several other kinases, including isoforms p38 and p38
(Miwatashi et al., 2005). However, more recent analysis of the
selectivity of TAK-715 over a wider range of human protein
kinases showed this compound to be relatively nonselective.
TAK-715 was reported to inhibit 22 kinases by more than
80% when screened at 10 mM (Verkaar et al., 2011). The five
specified kinases all contained Thr or Met gatekeepers and
thus a similar pattern to that observed for SB-203580 appears
to exist for selectivity and gatekeeper identity. Analysis of
X-ray structures and contact residues (see below) shows that
there is little structural difference between TAK-715 and SB-
203580. For TAK-715, the contact-residue analysis (cutoff at
4 A˚) indicates one extra interaction with Gly110 at the end of
the hinge, while the X-ray structure indicates some longer
range hydrophobic interactions with the front benzamide of
the inhibitor. Overall, the type and numbers of protein–ligand
interactions are similar for both the SB-203580 and TAK-715
complexes and this is reflected in similar kinase-selectivity
profiles.
Both SCIO-469 and VX-745 are highly selective p38
inhibitors (Karaman et al., 2008; Verkaar et al., 2011). The
compounds do not use all of the subpockets of the ATP-
binding region, but their interactions are optimized. In fact,
for SCIO-469 the only polar interactions observed are those
(i) between the carbonyl and the hinge and (ii) between the
substituted piperazine and the adenine region. Instead,
substantial hydrophobic interactions are observed in the front
and back pocket regions, two regions that are diverse in
protein kinases as they are not required for function/catalysis.
SCIO-469 has the extra amide group bound to the front
pocket, which could also interact with Arg49 of subdomain II.
This residue was identified as one of the contact residues
differing from those of VX-745 in our analysis.
The shape and properties of the front pocket in this protein
conformation are also a consequence of the main-chain
peptide flip that is observed in the hinge region between
Met109 and Gly110 for both SCIO-469 and VX-745. This
peptide flip is accessible because of the presence of Gly110,
which increases the conformational space around this residue.
Induction of the peptide flip is a feature shared by SCIO-469,
VX-745 and PH-797804. As all of these compounds have been
reported to be highly selective for p38, it is highly likely that
inhibitor-driven induction of the hinge flip is a major contri-
butor to selectivity. The curled conformation of the Gly-rich
loop should also add to the selectivity of SCIO-469, as this
conformation is stabilized by interaction with the ligand.
Previously, it has been claimed that adoption of the inactive
DFG-out conformation would correlate with improved
selectivity (Liu & Gray, 2006; Mol et al., 2004; Simard et al.,
2009). This cannot be confirmed from this study, as the least
selective compounds both show this fold whilst SCIO-469 does
not and VX-745 has either an ‘in’ conformation or an unusual
‘out’ position.
Analysis of the contact residues that are within a distance of
4 A˚ of these four ligands (Fig. 6a) shows that both TAK-715
(Fig. 6b) and SB-203580 make a total of 18 contacts with the
protein, whilst SCIO-469 and VX-745 make 23 and 24 inter-
actions, respectively. For these inhibitors, the relatively large
number of contact residues results in improved selectivity, as
the combination of interactions becomes more kinase-specific
with a larger numbers of contacts. For a more specific deter-
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Figure 6
(a) Occurrence of p38 contact residues in the presented structures, i.e.
residues that are within 4 A˚ distance of any of the four ligands in these
p38 cocrystal structures. The occurrence (in %) of each contact residue
in the human protein kinase multiple sequence alignment is given.
Contacts with (1) TAK-715, (2) SB-203580, (3) SCIO-469 and (4) VX-745
are indicated for each residue. (b) Mapping of contact residues of TAK-
715 onto the complex structure. Different colours represent different
subdomains from the Hunter classification (Hanks & Hunter, 1995; not
shown).
mination of the contribution of each of these residues, they
were implemented in the human eukaryotic protein kinase
(ePK) multiple sequence alignment (http://kinase.com/human/
kinome/groups/ePK.aln; Manning et al., 2002). This enables
calculation of how often each of these residues occurs in the
human kinome (Fig. 6a). The major differences between VX-
745/SCIO-469 and SB-203580/TAK-715 are the interactions at
the end of the hinge and in the front pocket. In addition to
inducing the hinge flip, the more selective compounds occupy
a larger volume in the front pocket, making contacts with
Ala111, Asp112 and Asn115. Each of these three residues has
an occurrence of less than 10% at these positions in the
kinome, making them hotspots for improving kinase selec-
tivity towards p38. To relate the measured kinase selectivity
to the underlying protein–ligand interactions, the average
occurrence of contact residues in the kinome was calculated
for each of the four inhibitors described in this paper. The
average occurrences for SB-203580, TAK-715, VX-745 and
SCIO-469 were 47, 45, 39 and 32%, respectively. Once again,
this correlates well with their selectivity profiles, as VX-745
and SCIO-469 have more interactions with amino acids that
occur less often in the kinome. These calculations were also
performed for the MAPK subset of the human kinome. As
expected, the occurrences of the contact residues are higher in
the MAPK subset (70, 66, 64 and 58%, respectively) but the
overall trend is the same.
In conclusion, we present the X-ray structures of four p38–
inhibitor complexes, one of which is presented for the first
time, and relate the protein conformation to observed kinase
selectivity profiles. We show that the choice of experimental
conditions, in particular the use of cocrystallization rather
than soaking, has a significant impact on the conformation of
p38–inhibitor complexes. For this reason, we advise that not
only the structures of inhibitors in complex with the protein
kinase of interest should be determined, but that the crystal-
lization of public domain complexes under the same condi-
tions should also be attempted whenever possible in order to
be able to extract meaningful comparisons between structures.
The highly selective p38 inhibitors SCIO-469 and VX-745
induce an unusual peptide flip. SCIO-469 also induces a
collapsed Gly-rich loop, whilst the DFG sequence in VX-745
adopts the rare DFG-out conformation. Contact-residue
analysis shows that the latter two inhibitors make more
interactions with the protein than the less selective inhibitors
SB-203580 and TAK-715 and make more interactions with
residues that are less conserved within the human kinome.
We thank Joost Uitdehaag for generation of the expression
construct for p38 and Wim Koot for performing large-scale
fermentor expression cultures.
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